Advertisement

Gastroenterology Editors' Choice: Top Stories of 2013

Letter to Readers |
December 27, 2013

Gastroenterology Editors' Choice: Top Stories of 2013

  1. M. Brian Fennerty, MD

A perspective on the most important research in the field from the past year

  1. M. Brian Fennerty, MD

It's time again for me to choose the most important stories of the year — this year, as NEJM Journal Watch Gastroenterology. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do that better than ever. This year, I focused on stories that informed changes in my own practice. Here's a brief overview.

In inflammatory bowel disease, the issues I found most important were loss of response to tumor necrosis factor α agents and its prevention with adjunctive immunomodulator therapy, as well as management of loss of response based on blood testing for serum levels and antibodies.

In colonoscopy, further documentation of its effectiveness in preventing colorectal cancer was critical, as was the observation that simply measuring performance improves the quality of the exams. Also, the confusion surrounding serrated lesions was lessened by the endoscopic description of these lesions.

Fatty liver disease is our “growth” issue in liver disease, and we now have further evidence that it contributes more each year to liver failure and cancer. On the bright side, simple measures such as weight loss and exercise may prevent progression of disease.

Finally, up north in the esophagus, eosinophilic esophagitis remains of importance, proton-pump inhibitors seem to be more important than steroids in managing this disease, and the final days of routine surveillance in all patients with Barrett esophagus may be on the horizon.

The top gastroenterology stories of 2013 are:

Inflammatory Bowel Disease

Development of Antibodies to Infliximab in IBD

Use Blood Tests to Manage Loss of Response to Infliximab

Colonoscopy

Colonoscopy Works!

Just Measuring Quality Improves Colonoscopy Performance

Endoscopic Features of Sessile Serrated Polyps Identified

Liver Disease

Diabetes and Obesity Greatly Contribute to Hepatocellular Carcinoma

Aerobic or Resistance Training for Nonalcoholic Fatty Liver Disease?

Promote Weight Loss in Patients with NAFLD

Esophageal Disease

PPIs Better Than Topical Steroids for Eosinophilic Esophagitis

Surveillance of Nondysplastic Barrett Esophagus Is Not Supportable

It has been another year full of critical information that changed my practice. I hope we were able to not only inform your practice, but to help change it as well.

As always, we count on your feedback to provide the most clinically relevant medical information to help you in your practices, so please send us your comments and suggestions at https://secure.jwatch.org/site/contactus.

Happy holidays to all of you.

  • Disclosures for M. Brian Fennerty, MD at time of publication Royalties Pfizer; Takeda Editorial boards Alimentary Pharmacology and Therapeutics

Reader Comments (1)

JOAO GROSSI Resident, Surgery, Specialized, bRASIL

VERY GOOD
the articles are most important use to good pratice in medicine actually.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement